Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [21] Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
    Davids, Matthew S.
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Ng, Samuel
    Kim, Austin I.
    Weinstock, Matthew
    Lowney, Jessica
    Pazienza, Samantha
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    LaCasce, Ann S.
    Armand, Philippe
    Arnason, Jon E.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2020, 136
  • [22] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
    Cho, Sang Kyu
    Manzoor, Beenish
    Sail, Kavita
    Ravelo, Arliene
    Shapouri, Sheila
    Sharmokh, Simon
    Kapustyan, Tatyana
    Johnson, Scott
    Parise, Helene
    Virabhak, Suchin
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57
  • [23] Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
    Al-Sawaf, Othman
    Zhang, Can
    Tandon, Maneesh
    Sinha, Arijit
    Fink, Anna-Maria
    Robrecht, Sandra
    Samoylova, Olga
    Liberati, Anna M.
    Pinilla-Ibarz, Javier
    Opat, Stephen
    Sivcheva, Liliya
    Le Du, Katell
    Fogliatto, Laura M.
    Niemann, Carsten U.
    Weinkove, Robert
    Robinson, Sue
    Kipps, Thomas J.
    Tausch, Eugen
    Schary, William
    Ritgen, Matthias
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    LANCET ONCOLOGY, 2020, 21 (09): : 1188 - 1200
  • [24] Addition of acalabrutinib to obinutuzumab-venetoclax for treatment of relapsed or refractory chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (06): : 256 - 257
  • [25] A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma
    Othman, Tamer
    Rosenberg, Aaron S.
    Timmerman, John
    Heyman, Benjamin
    Abdulhaq, Haifaa
    Tuscano, Joseph M.
    BLOOD, 2022, 140 : 11954 - 11955
  • [26] CHEMOIMMUNOTHERAPY WITH OFATUMUMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PHASE II INTERNATIONAL TRIAL
    Wierda, G.
    Kipps, T.
    Duerig, J.
    Griskevicius, L.
    Stilgenbauer, S.
    Mayer, J.
    Smolej, L.
    Hess, G.
    Griniute, R.
    Hernandez-Ilizaliturri, F.
    Padmanabhan, S.
    Gorczyca, M.
    Gupta, I.
    Nielsen, T.
    Russell, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 320 - 321
  • [27] Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Dreyling, Martin H.
    Opat, Stephen
    Owen, Carolyn J.
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod A.
    Tausch, Eugen
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Langerak, Anton W.
    van Dongen, Jacques J. M.
    Ritgen, Matthias
    Boettcher, Sebastian
    Stilgenbauer, Stephan
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [28] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
    Hill, Brian T.
    Kalaycio, Matt
    ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
  • [29] COST-EFFECTIVENESS OF OBINUTUZUMAB IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Reyes, C.
    Gazauskas, G.
    Veentra, D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
    Alrawashdh, Neda
    McBride, Ali
    Abraham, Ivo
    BLOOD, 2022, 140 : 2155 - 2156
12345